Literature DB >> 21719885

Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases.

Ralf Trappe1, Heiner Zimmermann, Susanne Fink, Petra Reinke, Martin Dreyling, Andreas Pascher, Hans Lehmkuhl, Barbara Gärtner, Ioannis Anagnostopoulos, Hanno Riess.   

Abstract

Post-transplantation lymphoproliferative disorder (PTLD) with plasmacellular differentiation has been reported as a rare subtype of monomorphic B-cell post-transplant lympho-proliferation with histological and immunophenotypical features of plasmacytoma in the non-transplant population. Here we present clinical, laboratory and histopathological features, treatment and outcome of 8 patients from the German prospective PTLD registry. Clinically, extranodal manifestations were common while osteolytic lesions were rare and none of the patients had bone marrow involvement. Immunohistochemistry showed light chain restriction and expression of CD138 without CD20 expression in all samples. An association with Epstein-Barr virus was found in 3 out of 8 cases. We suggest that the Ann Arbor classification is most useful for this disease entity and report a generally good response to treatment including reduction of immuno-suppression, surgery and irradiation in localized disease and systemic chemotherapy analogous to plasmacell myeloma in advanced disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719885      PMCID: PMC3128229          DOI: 10.3324/haematol.2010.039214

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  23 in total

Review 1.  Post-transplant plasma cell myeloma and polymorphic lymphoproliferative disorder with monoclonal serum protein occurring in solid organ transplant recipients.

Authors:  Xiaoping Sun; LoAnn C Peterson; Yun Gong; Ann E Traynor; Beverly P Nelson
Journal:  Mod Pathol       Date:  2004-04       Impact factor: 7.842

2.  Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop.

Authors:  N L Harris; J A Ferry; S H Swerdlow
Journal:  Semin Diagn Pathol       Date:  1997-02       Impact factor: 3.464

Review 3.  Thoracic and abdominal manifestations of lymphoma occurring in the immunocompromised patient.

Authors:  G D Dodd; D P Greenler; S R Confer
Journal:  Radiol Clin North Am       Date:  1992-05       Impact factor: 2.303

4.  The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies.

Authors:  S M Meehan; P Domer; M Josephson; M Donoghue; A Sadhu; L T Ho; A J Aronson; J R Thistlethwaite; M Haas
Journal:  Hum Pathol       Date:  2001-02       Impact factor: 3.466

5.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

Authors:  T E Starzl; M A Nalesnik; K A Porter; M Ho; S Iwatsuki; B P Griffith; J T Rosenthal; T R Hakala; B W Shaw; R L Hardesty
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

6.  Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders.

Authors:  D M Knowles; E Cesarman; A Chadburn; G Frizzera; J Chen; E A Rose; R E Michler
Journal:  Blood       Date:  1995-01-15       Impact factor: 22.113

7.  Malignant lymphomas in transplantation patients.

Authors:  I Penn; W Hammond; L Brettschneider; T E Starzl
Journal:  Transplant Proc       Date:  1969-03       Impact factor: 1.066

8.  Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients.

Authors:  D E Tsai; C L Hardy; J E Tomaszewski; R M Kotloff; K M Oltoff; B G Somer; S J Schuster; D L Porter; K T Montone; E A Stadtmauer
Journal:  Transplantation       Date:  2001-04-27       Impact factor: 4.939

9.  Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.

Authors:  S A Riddler; M C Breinig; J L McKnight
Journal:  Blood       Date:  1994-08-01       Impact factor: 22.113

10.  Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease.

Authors:  D N Kenagy; Y Schlesinger; K Weck; J H Ritter; M M Gaudreault-Keener; G A Storch
Journal:  Transplantation       Date:  1995-09-27       Impact factor: 4.939

View more
  17 in total

1.  Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature.

Authors:  Tzu-Fei Wang; Jonathan L Klein; Pamela K Woodard; Anjum Hassan; Susan M Joseph; Gregory A Ewald; Geoffrey L Uy
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

2.  Autologous stem cell transplantation in EBV-positive post-renal transplant refractory multiple myeloma: A case report and literature review.

Authors:  Xiaobao Xie; Yan Lin; Yang Cao; Weimin Dong; Wei Wu; Yuandong Zhu; Deliang Liu; Haiqian Li; Qing Li; Weiying Gu
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

Review 3.  Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.

Authors:  Ajay Major; Manali Kamdar
Journal:  Curr Treat Options Oncol       Date:  2018-05-24

4.  Mutlifocal osseous posttransplantation lymphoproliferative disorder: case report.

Authors:  Ryan Lo; Zachary Michalicek; Martin Lazarus
Journal:  Skeletal Radiol       Date:  2015-02-14       Impact factor: 2.199

5.  Successful treatment with lenalidomide of secondary multiple myeloma with extramedullary liver plasmacytoma in a renal transplant recipient: A case report and review of the literature.

Authors:  Xiaobao Xie; Wei Wu; Yuandong Zhu; Deliang Liu; Weimin Dong; Haiqian Li; Qing Li; Weiying Gu
Journal:  Oncol Lett       Date:  2015-09-18       Impact factor: 2.967

6.  Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders.

Authors:  Aaron S Rosenberg; Robin Ruthazer; Jessica K Paulus; David M Kent; Andrew M Evens; Andreas K Klein
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-09-17

7.  Cancer Risk After Pediatric Solid Organ Transplantation.

Authors:  Elizabeth L Yanik; Jodi M Smith; Meredith S Shiels; Christina A Clarke; Charles F Lynch; Amy R Kahn; Lori Koch; Karen S Pawlish; Eric A Engels
Journal:  Pediatrics       Date:  2017-05       Impact factor: 7.124

Review 8.  Occurrence of Epstein-Barr virus-associated plasmacytic lymphoproliferative disorder after antithymocyte globulin therapy for aplastic anemia: a case report with review of the literature.

Authors:  Ryota Nakanishi; Mitsuaki Ishida; Keiko Hodohara; Hiroko Okuno; Miyuki Yoshii; Akiko Horinouchi; Ayaka Shirakawa; Ayumi Harada; Muneo Iwai; Keiko Yoshida; Akiko Kagotani; Takashi Yoshida; Hidetoshi Okabe
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

9.  Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.

Authors:  Ding-Bao Chen; Qiu-Jing Song; Yun-Xin Chen; Yu-Hong Chen; Dan-Hua Shen
Journal:  Int J Hematol       Date:  2012-12-20       Impact factor: 2.490

10.  Therapeutic options in post-transplant lymphoproliferative disorders.

Authors:  Heiner Zimmermann; Ralf Ulrich Trappe
Journal:  Ther Adv Hematol       Date:  2011-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.